Myofibroblast and pro-fibrotic cytokines in fibrosis of IgG4-related disease (IgG4-RD) patients from South Asia: preliminary data
Introduction Fibrosis is a typical pathological characteristic in IgG4-RD patients and often irreversible. There exists a lack of suitable markers for detection of earlier onset of fibrosis in various organs in IgG4-RD patients. Hence, this study aims at analysing ambispectively the myofibroblasts and the pro-fibrotic cytokines, IFN gamma and IL-33 involved in IgG4-RD associated fibrosis in South Asian patients. Method Archived biopsy samples of definite/probable/possible cases of IgG4-RD, classified according to diagnostic criteria, taken from patients who attended the OPD and IPD of our tertiary care centre during January 2015–January 2020 were chosen for this study. The paraffin sections were examined qualitatively for fibrosis and the excessive collagen deposition by Hematoxylin & Eosin and Masson’s Trichrome staining. Also, the presence of alpha-Smooth muscle actin (α-SMA) expressing myofibroblasts and the involvement of pro-fibrotic cytokines (IFN-gamma, IL-33) were assessed by Immunohistochemistry and scored semi-quantitatively (+mild, ++moderate, +++ severe). Serum IL-33 levels were analysed by indirect Elisa (R & D Systems). Results Myofibroblasts were present in 10/12 biopsy samples, in moderate levels in 4 (33%) and very high levels (+++) in 3 (25%) of the patients. IFN-gamma was expressed at low levels in 6 (50%) and absent in 6 (50%). All patients showed IL-33 expression with very high levels in tissue (6, 50%), as well as in serum samples. Conclusion The findings of this study reinforce the role of myofibroblasts and profibrotic cytokines like IL-33 in fibrosis of Ig4-RD patients, pointing to their potential as earlier predictive markers of onset and extent of fibrosis..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
Clinical rheumatology - 43(2024), 3 vom: 03. Feb., Seite 1103-1110 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Joseph, Josna [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Fibrosis |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR) 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s10067-023-06861-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR054817951 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR054817951 | ||
| 003 | DE-627 | ||
| 005 | 20240220064715.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240220s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10067-023-06861-9 |2 doi | |
| 035 | |a (DE-627)SPR054817951 | ||
| 035 | |a (SPR)s10067-023-06861-9-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Joseph, Josna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Myofibroblast and pro-fibrotic cytokines in fibrosis of IgG4-related disease (IgG4-RD) patients from South Asia: preliminary data |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR) 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Introduction Fibrosis is a typical pathological characteristic in IgG4-RD patients and often irreversible. There exists a lack of suitable markers for detection of earlier onset of fibrosis in various organs in IgG4-RD patients. Hence, this study aims at analysing ambispectively the myofibroblasts and the pro-fibrotic cytokines, IFN gamma and IL-33 involved in IgG4-RD associated fibrosis in South Asian patients. Method Archived biopsy samples of definite/probable/possible cases of IgG4-RD, classified according to diagnostic criteria, taken from patients who attended the OPD and IPD of our tertiary care centre during January 2015–January 2020 were chosen for this study. The paraffin sections were examined qualitatively for fibrosis and the excessive collagen deposition by Hematoxylin & Eosin and Masson’s Trichrome staining. Also, the presence of alpha-Smooth muscle actin (α-SMA) expressing myofibroblasts and the involvement of pro-fibrotic cytokines (IFN-gamma, IL-33) were assessed by Immunohistochemistry and scored semi-quantitatively (+mild, ++moderate, +++ severe). Serum IL-33 levels were analysed by indirect Elisa (R & D Systems). Results Myofibroblasts were present in 10/12 biopsy samples, in moderate levels in 4 (33%) and very high levels (+++) in 3 (25%) of the patients. IFN-gamma was expressed at low levels in 6 (50%) and absent in 6 (50%). All patients showed IL-33 expression with very high levels in tissue (6, 50%), as well as in serum samples. Conclusion The findings of this study reinforce the role of myofibroblasts and profibrotic cytokines like IL-33 in fibrosis of Ig4-RD patients, pointing to their potential as earlier predictive markers of onset and extent of fibrosis. | ||
| 650 | 4 | |a IgG4-related disease |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Fibrosis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Myofibroblasts |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Profibrotic cytokines |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a IL-33 |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Prabhu, V. |4 aut | |
| 700 | 1 | |a Thomas, Meera |4 aut | |
| 700 | 1 | |a Karuppusami, Reka |4 aut | |
| 700 | 1 | |a Kodiatte, Thomas Alex |4 aut | |
| 700 | 1 | |a Michael, Rajiv |4 aut | |
| 700 | 1 | |a Rymbai, Manbha L. |4 aut | |
| 700 | 1 | |a Mathew, John |0 (orcid)0000-0002-9857-2271 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical rheumatology |d London : Springer, 1982 |g 43(2024), 3 vom: 03. Feb., Seite 1103-1110 |w (DE-627)SPR008480389 |w (DE-600)1480901-1 |x 1434-9949 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2024 |g number:3 |g day:03 |g month:02 |g pages:1103-1110 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10067-023-06861-9 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2024 |e 3 |b 03 |c 02 |h 1103-1110 | ||